Thyrocare Technologies, a leading healthcare diagnostics firm, has unveiled its new GLP-1 Health Check, a set of comprehensive diagnostic packages with up to 81 tests designed to monitor patients before, during, and after GLP-1 therapy.

Priced from Rs. 2,799 and available nationwide, the packages aim to equip patients and doctors with critical health insights at every stage of treatment, the pharma company has said.

GLP-1 (Glucagon-Like Peptide-1) is a natural hormone that regulates blood sugar, controls appetite, and slows digestion. GLP-1 agonist medications, increasingly prescribed for obesity and type 2 diabetes, mimic this hormone. Their rising popularity for weight loss has heightened the need for continuous medical monitoring to ensure safety and effectiveness.

Thyrocare’s new packages help patients establish a health baseline, track therapy progress, and detect side effects early. The tests cover lipid profiles, fasting glucose, insulin resistance, liver and kidney function, cardiac risk markers, vitamin levels, pancreatic and thyroid health, addressing the full spectrum of risks linked to GLP-1 therapy.

“GLP-1-based medicines are powerful tools for diabetes and weight management, but they work best when paired with consistent monitoring,” said Rahul Guha, MD & CEO, Thyrocare Technologies Ltd. “Our packages make it simple for patients across India to access reliable diagnostic support and track their health safely.”

Shehla Shaikh, an endocrinologist, added, “With obesity emerging as a global health challenge, structured monitoring is essential. Comprehensive testing ensures nutritional balance, organ health, and long-term safety during GLP-1 therapy.”